LGVN Q3 2021 Earnings — Longeveron Inc. Revenue & Financial Results | Market Cap Arena

LGVNLongeveron Inc.

$18M

Q3 2021 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$232,000-87.6% YoY

Gross Profit

$164,00070.7% margin

Operating Income

-$5M-2114.2% margin

Net Income

-$5M-2092.7% margin

EPS (Diluted)

$-2.50

QoQ Revenue Growth

-52.6%

Cash Flow

Operating Cash Flow

-$2M

Free Cash Flow

-$2M

Stock-Based Comp.

$3M

Balance Sheet

Total Assets

$27M

Total Liabilities

$5M

Stockholders' Equity

$22M

Cash & Equivalents

$10M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$232,000	$2M	-87.6%
Gross Profit	$164,000	$373,000	-56.0%
Operating Income	-$5M	-$958,000	-412.0%
Net Income	-$5M	-$938,000	-417.6%